SANTEN PHARMACEUTICAL CO.,LTD., July-September (2Q) Net Income Decreases by 8%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Nov 7, 2024 3:00 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE-P] announced its financial results (based on IFRS) in the afternoon session on November 7th (15:00). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2025 (April to September) was 18.7 billion yen, a 2.6% decrease compared to the same period last year. The progress rate against the 33.5 billion yen full-year plan was 56.0%, below the five-year average of 82.2%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the October to March period (second half) is expected to expand by 86.5% from the same period last year, reaching 13.7 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated net income decreased to 8.13 billion yen, a 8.2% decrease compared to the same period last year. The operating profit margin decreased from 16.8% in the same period last year to 15.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	128,915	-19,021	-19,103	-22,041	-56.1	ー	Nov 8, 2022	IFRS
Apr - Sep, 2023	145,806	25,099	24,075	19,280	52.1	80.6	Nov 7, 2023	IFRS
Apr - Sep, 2024	146,404	23,873	23,839	18,772	52.9	53.0	Nov 7, 2024	IFRS
YoY	+0.4%	-4.9%	-1.0%	-2.6%	+1.6%

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024 Guidance	ー	ー	ー	ー	－	17	May 9, 2024	IFRS
Apr - Sep, 2024 Results	146,404	23,873	23,839	18,772	52.9	17	Nov 7, 2024	IFRS
Revision Rate	－	－	－	－	－

Guidance Update

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	302,000	44,500	45,000	ー	－	34	Aug 6, 2024	IFRS
Mar, 2025 New	302,000	44,500	45,000	32,500	95.2	34	Nov 7, 2024	IFRS
Revision Rate	0.0%	0.0%	0.0%	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	156,159	13,442	5,799	7,362	20.1	17	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	155,596	20,627	21,161	13,728	40.2	17	Nov 7, 2024	IFRS
YoY	-0.4%	+53.5%	+264.9%	+86.5%	+100.5%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	279,037	-3,090	-5,799	-14,948	-38.6	32	May 11, 2023	IFRS
Mar, 2024	301,965	38,541	29,874	26,642	72.6	33	May 9, 2024	IFRS
Mar, 2025 Guidance	302,000	44,500	45,000	32,500	95.2	34	Nov 7, 2024	IFRS
YoY	+0.0%	+15.5%	+50.6%	+22.0%	+31.2%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2023	73,417	12,349	11,207	8,866	23.9	16.8	Nov 7, 2023	IFRS
Oct - Dec, 2023	77,027	11,058	9,484	7,333	19.9	14.4	Feb 8, 2024	IFRS
Jan - Mar, 2024	79,132	2,384	-3,685	29	0.1	3.0	May 9, 2024	IFRS
Apr - Jun, 2024	74,771	13,155	13,450	10,633	29.6	17.6	Aug 6, 2024	IFRS
Jul - Sep, 2024	71,633	10,718	10,389	8,139	22.9	15.0	Nov 7, 2024	IFRS
YoY	-2.4%	-13.2%	-7.3%	-8.2%	-4.2%